We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
Humanin is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Humanin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2001–2018.
Based on 5 studies
Confidence
LowBy outcome
The current evidence for Humanin is insufficient to assign an evidence score, based on 5 indexed studies. A mitochondrial-derived peptide (a sibling of MOTS-c) studied for cytoprotection, neuroprotection, and metabolic effects. Honest appraisal: the evidence is almost entirely cell-culture and animal work plus human biomarker associations — there are no human efficacy trials of administered humanin. Research-use-only. Representative study: PMID 11717357.
The commonly studied dose of Humanin is No validated human dose. Humanin and analogs are research tools; any grey-market injectable dosing is anecdotal and unsupported by human trials.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Dihexa
Mostly mechanism / observationalA synthetic angiotensin-IV-derived peptide developed as a procognitive/anti-dementia research compound, promoted online as a potent nootropic. Honest appraisal: all efficacy data are in rodents and cell culture — there are no published human trials. Research-use-only.
Lactotripeptides
Mostly mechanism / observationalLast reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Humanin (mitochondrial-derived peptide)
A mitochondrial-derived peptide (a sibling of MOTS-c) studied for cytoprotection, neuroprotection, and metabolic effects. Honest appraisal: the evidence is almost entirely cell-culture and animal work plus human biomarker associations — there are no human efficacy trials of administered humanin. Research-use-only.
Humanin's cytoprotective, neuroprotective, and metabolic effects are demonstrated almost exclusively in cell and animal models, with human data limited to biomarker associations; there are no human efficacy trials of administered humanin, so the evidence is preclinical-only.
Humanin is a small peptide encoded within the mitochondrial 16S rRNA gene — one of the 'mitochondrial-derived peptides' (MDPs) that also includes MOTS-c.
It was first identified as a factor that protects neurons against amyloid-beta and familial Alzheimer's mutations in vitro, and has since been studied for cytoprotective, anti-apoptotic, neuroprotective, and insulin-sensitizing effects in cell and animal models.
Circulating humanin levels decline with age and have been associated, in human observational studies, with metabolic and cardiovascular status — which is why it is discussed as a longevity/biomarker peptide.
The honest evidence picture is that essentially all functional data come from in-vitro systems and rodent models (often using the more potent analog HNG), while human data are limited to correlational biomarker studies; there are no published randomized controlled trials of administered humanin for any indication.
It is not an approved drug or a regulated dietary supplement — grey-market 'humanin' is sold as a research peptide with the usual sourcing, purity, and sterility risks of any injectable from that market, and its long-term safety in humans is unknown.
The score reflects mechanistically interesting but preclinical-only and biomarker-level evidence.
Humanin binds pro-apoptotic factors (e.g., BAX) and engages a cell-surface receptor complex to suppress stress-induced apoptosis in cell models — the basis of its proposed neuroprotection.
As a peptide encoded in mitochondrial DNA, humanin is part of a retrograde signaling system that helps preserve mitochondrial function under stress.
In rodent models humanin and analogs improve insulin sensitivity and glucose handling, suggesting metabolic roles that remain unconfirmed in humans.
How Humanin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated human dose. Humanin and analogs are research tools; any grey-market injectable dosing is anecdotal and unsupported by human trials.
Can be taken without food
| Form | Type |
|---|---|
| 💊None established (research peptide) | Recommended |
Studied as injectable peptide / analog (HNG) in animals; grey-market 'humanin' is sold as a lyophilized powder for reconstitution with no clinical validation.
Minimum: 4 weeks
Optimal: 8 weeks
Cycling: Not required
Note: No validated human dosing or schedule exists — humanin is a research peptide, not a clinical therapy.
Dose-response data unavailable. The current published research for Humanin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Protects neurons against amyloid-beta and other insults in cell and animal models — not demonstrated in human trials.
Improves insulin sensitivity and reduces some markers of metabolic stress in animals; human evidence is correlational only.
No randomized controlled trials of administered humanin exist; human data are biomarker associations, not interventions.
Long-term safety of injected humanin in people is unstudied; grey-market sourcing adds purity and sterility risk.
Avoid — no human safety data.
Caution — a cytoprotective/anti-apoptotic peptide of unknown effect on tumor cells in humans.
Research-use-only; not validated or recommended for human use.
Tip: No human safety data; effects are unquantified.
Tip: Inherent to grey-market self-injected peptides; sterility unverified.
Timing is flexible for Humanin — consistent daily use matters more than the time of day. No validated human dosing or schedule; research-use-only peptide.
Humanin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are unknown human effects, injection-site reaction / infection. Use caution if any of these apply to you: Pregnancy / breastfeeding; Any non-research human use (no safety data).
Two milk-casein-derived tripeptides — Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) — produced by fermenting milk with Lactobacillus helveticus or hydrolysing casein. They inhibit ACE in vitro and have been studied extensively for blood pressure. Honest appraisal: multiple meta-analyses find a small, statistically-significant drop in systolic/diastolic BP, but the effect is modest, heterogeneous, larger in Japanese than Western trials, and dented by clear publication bias plus outright-null trials (e.g. the Dutch Engberink RCT).